Un abonnement à JoVE est nécessaire pour voir ce contenu. Connectez-vous ou commencez votre essai gratuit.
Method Article
This protocol will demonstrate the extraction and analysis of free and esterified bioactive fatty acids from cells. Fatty acids are accurately quantified using stable isotope dilution, chiral liquid chromatography, electron capture atmospheric chemical ionization multiple reaction monitoring mass spectrometry (SID-LC-ECAPCI-MRM/MS).
The metabolism of fatty acids, such as arachidonic acid (AA) and linoleic acid (LA), results in the formation of oxidized bioactive lipids, including numerous stereoisomers1,2. These metabolites can be formed from free or esterified fatty acids. Many of these oxidized metabolites have biological activity and have been implicated in various diseases including cardiovascular and neurodegenerative diseases, asthma, and cancer3-7. Oxidized bioactive lipids can be formed enzymatically or by reactive oxygen species (ROS). Enzymes that metabolize fatty acids include cyclooxygenase (COX), lipoxygenase (LO), and cytochromes P450 (CYPs)1,8. Enzymatic metabolism results in enantioselective formation whereas ROS oxidation results in the racemic formation of products.
While this protocol focuses primarily on the analysis of AA- and some LA-derived bioactive metabolites; it could be easily applied to metabolites of other fatty acids. Bioactive lipids are extracted from cell lysate or media using liquid-liquid (l-l) extraction. At the beginning of the l-l extraction process, stable isotope internal standards are added to account for errors during sample preparation. Stable isotope dilution (SID) also accounts for any differences, such as ion suppression, that metabolites may experience during the mass spectrometry (MS) analysis9. After the extraction, derivatization with an electron capture (EC) reagent, pentafluorylbenzyl bromide (PFB) is employed to increase detection sensitivity10,11. Multiple reaction monitoring (MRM) is used to increase the selectivity of the MS analysis. Before MS analysis, lipids are separated using chiral normal phase high performance liquid chromatography (HPLC). The HPLC conditions are optimized to separate the enantiomers and various stereoisomers of the monitored lipids12. This specific LC-MS method monitors prostaglandins (PGs), isoprostanes (isoPs), hydroxyeicosatetraenoic acids (HETEs), hydroxyoctadecadienoic acids (HODEs), oxoeicosatetraenoic acids (oxoETEs) and oxooctadecadienoic acids (oxoODEs); however, the HPLC and MS parameters can be optimized to include any fatty acid metabolites13.
Most of the currently available bioanalytical methods do not take into account the separate quantification of enantiomers. This is extremely important when trying to deduce whether or not the metabolites were formed enzymatically or by ROS. Additionally, the ratios of the enantiomers may provide evidence for a specific enzymatic pathway of formation. The use of SID allows for accurate quantification of metabolites and accounts for any sample loss during preparation as well as the differences experienced during ionization. Using the PFB electron capture reagent increases the sensitivity of detection by two orders of magnitude over conventional APCI methods. Overall, this method, SID-LC-EC-atmospheric pressure chemical ionization APCI-MRM/MS, is one of the most sensitive, selective, and accurate methods of quantification for bioactive lipids.
1. Standard and Internal Standard Mixes
2. Collection of Media and Cell Lysate
3. Extraction of Lipids from Media
4. Extraction of Lipids from Cell Lysate
5. Pentafluorylbenzylbromide (PFB) Derivatization
6. Stable Isotope Dilution Chiral Liquid Chromatography Electron Capture Atmospheric Pressure Chemical Ionization Mass Spectrometry (SID-LC-ECAPCI-MS) Analysis
7. Representative Results:
The chromatograms in Figure 1 are representative of a targeted lipidomics profile. The first panel (Figure 1A) shows 13- and 9-HODE along with the corresponding 13- and 9-oxoODE, derived from linoleic acid. In addition, 15-oxoETE, the oxidized metabolite of 15-HETE is also shown in the second panel. The bottom two panels show 20-HETE and the 20-HETE-IS, [2H6]-20-HETE. Figure 1B shows the separation and unique transitions determined for the HETE stereoisomers that result from enzymatic oxidation of AA or by ROS. Figure 1C is a representation of PGs, isoPs, and LTB4. Some of the standards do not have a deuterated IS commercially available; therefore, an IS that is similar in retention time is used for quantification. For instance, [2H8]-12(S)-HETE is used to quantify 11-HETE and 8-HETE species in addition to 12(R)-HETE and 12(S)-HETE.
From the representative chromatograms, it is evident that there is a small shift in the retention of the deuterated IS compared to the unlabeled standard. This shift to a later retention time is a result of the deuterium interaction with the normal phase column. Deuterium is more polar than hydrogen; therefore, there is a stronger interaction with the normal phase of the column. If this separation were taking place using a reversed phase column, the shift would be to an earlier retention time as a more polar moiety would have a weaker interaction with the reversed phase.
Figure 1. This figure is a representative example of a targeted lipidomics analysis. Figure 1A shows the total ion chromatograms (TIC) for several LA and AA oxidized metabolites including 13-oxoODE and 9-oxoODE in the first panel, 15-oxoETE in the second panel, 13-HODE and 9-HODE (panels 3 & 5) and 20-HETE (panel 7). The HODEs and 20-HETE have a corresponding deuterated IS in the panel below (4, 6, & 8). The TICs in Figure 2B show the separation and unique transitions of the HETE stereoisomers derived from AA. Figure 2C is a representation of PGs, isoPs, and LTs. The collision energy (CE), MRM transitions, and retention time (RT, min) were optimized using a Waters 2695 LC coupled to a Thermo Fisher TSQ Quantum Ultra and are listed in Table 3 for each compound.
Time (min) | % A | % B |
0 | 98 | 2 |
3 | 98 | 2 |
11 | 96.4 | 3.6 |
15 | 92 | 8 |
27 | 92 | 8 |
30 | 50 | 50 |
38 | 50 | 50 |
39 | 98 | 2 |
45 | 98 | 2 |
Table 1. HPLC gradient conditions for the chiral normal phase lipidomics separation. Solvent A is 100% hexanes and Solvent B is methanol/isopropanol (1:1).
Mass Spectrometry Parameter | Setting |
Source | APCI |
Mode | Negative Ion |
Method Length | 40 min |
MRM Scan Width | 0.002 m/z |
MRM Scan Time | 0.15 sec |
MRM Peak Width | 0.70 FWHM |
Tube Lens | 164 V |
Source CID | 10 eV |
Q2 Collision Gas | 1.5 units |
Vaporizer Temperature | 450°C |
Capillary Temperature | 250°C |
Discharge Current | 0 μA |
Sheath Gas Pressure | 25 units |
Ion Sweep Pressure | 3 units |
Auxiliary Gas Pressure | 5 units |
Table 2. Listed above are the optimized mass spectrometry parameters for the measurement of bioactive lipids. These parameters are taken from a Thermo Fisher TSQ Quantum Ultra.
Compound | Transition | CE (eV) | RT (min) |
13-oxoODE | 293.03 → 113.10 | 21 | 9.9 |
9-oxoODE | 293.03 → 113.10 | 21 | 17.9 |
15-oxoETE | 317.05 → 113.18 | 18 | 8.1 |
13(R)-HODE | 295.03 → 195.12 | 18 | 12.5 |
13(S)-HODE | 295.03 → 195.12 | 18 | 14.8 |
[2H4]-13(S)-HODE | 299.03 → 198.12 | 18 | 14.9 |
9(R)-HODE | 295.03 → 171.10 | 18 | 13.7 |
9(S)-HODE | 295.03 → 171.10 | 18 | 21.2 |
[2H4]-9(S)-HODE | 299.03 → 172.12 | 18 | 21.2 |
20-HETE | 319.03 → 289.10 | 18 | 12.4 |
[2H6]-20-HETE | 325.03 → 295.10 | 18 | 12.4 |
5(R)-HETE | 319.04 → 115.04 | 16 | 15.7 |
5(S)-HETE | 319.04 → 115.04 | 16 | 16.2 |
[2H8]-5(S)-HETE | 327.04 → 116.04 | 16 | 16.4 |
12(R)-HETE | 319.04 → 179.11 | 14 | 11.7 |
12(S)-HETE | 319.04 → 179.11 | 14 | 12.3 |
[2H8]-12(S)-HETE | 327.13 → 184.11 | 14 | 12.5 |
15(R)-HETE | 319.04 → 219.12 | 13 | 12.4 |
15(S)-HETE | 319.04 → 219.12 | 13 | 15.9 |
[2H8]-15(S)-HETE | 327.03 → 226.12 | 13 | 16.1 |
11(R)-HETE | 319.04 → 167.11 | 16 | 11.1 |
11(S)-HETE | 319.04 → 167.11 | 16 | 12.5 |
8(R)-HETE | 319.04 → 155.09 | 16 | 11.7 |
8(S)-HETE | 319.04 → 155.09 | 16 | 12.6 |
LTB4 | 335.03 → 195.10 | 18 | 32.0 |
[2H4]-LTB4 | 339.03 → 197.10 | 18 | 32.0 |
PGE2 | 351.03 → 271.15 | 18 | 31.2 |
[2H4]-PGE2 | 355.03 → 275.15 | 18 | 31.2 |
PGD2 | 351.03 → 271.15 | 25 | 32.5 |
[2H4]-PGD2 | 355.03 → 275.15 | 25 | 32.5 |
8-iso-PGE2 | 351.03 → 271.15 | 18 | 37.4 |
11β-PGF2 | 353.03 → 193.11 | 25 | 27.6 |
[2H4]-11β-PGF2 | 357.03 → 197.11 | 25 | 27.6 |
PGF2α | 353.03 → 193.11 | 25 | 33.1 |
[2H4]-PGF2α | 357.03 → 197.11 | 25 | 33.1 |
8-iso-PGF2α | 353.03 → 193.11 | 25 | 34.4 |
[2H4]-8-iso-PGF2α | 357.03 → 197.11 | 25 | 34.4 |
Table 3. This table lists the compounds detected in the total ion chromatograms of Figure 1A-C. The second column provides the transition used for MRM/MS, the third column lists the collision energy (CE, eV) and the last column lists the retention time (RT, min). Parameters were optimized using a Waters 2695 separation module coupled to a Thermo Fisher TSQ Quantum Ultra.
The standards and internal standards used in this protocol provide a representation of a targeted lipidomics method. A Waters 2695 separation module and Thermo Fisher TSQ Quantum Ultra were used for the LC-MS analysis and the optimal parameter settings can be found in Tables 1 and 2. Additionally, this extraction protocol was designed for adherent cells, but can be modified for other cell types as well as other biological matrices including urine, blood, and tissue. Many lipid standards ...
No conflicts of interest declared.
Most current bioanalytical methods available for the measurement of bioactive lipids are not as extensive as they do not include chiral normal phase chromatography or SID. Chiral normal phase LC is critical for the separation of enantiomers and for being able to distinguish between enzyme- or ROS-mediated metabolism. The use of SID ensures that human error or complications that arise during extraction or analysis are taken into account during quantification. These added components along with ECAPCI-MRM make this the most sensitive, selective method available for the analysis of bioactive lipids.
Name | Company | Catalog Number | Comments |
5-oxo-6E,8Z,11Z,14Z-eicosatetraenoic-6,8,9,11,12,14,15-d7 acid | Cayman Chemical | 334250 | [2H7]-5-ox–TE Internal Standard |
5S-hydroxy-6E,8Z,11Z,14Z-eicosatetraenoic-5,6,8,9,11,12,14,15-d8 acid | Cayman Chemical | 334230 | [2H8]-5(S)-HETE Internal Standard |
12S-hydroxy-5Z,8Z,10E,14Z-eicosatetraenoic-5,6,8,9,11,12,14,15-d8 acid | Cayman Chemical | 334570 | [2H8]-12(S)-HETE Internal Standard |
15S-hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic-5,6,8,9,11,12,14,15-d8 acid | Cayman Chemical | 334720 | [2H8]-15(S)-HETE Internal Standard |
20-hydroxy-5Z,8Z,11Z,14Z-eicosatetraenoic-16,16,17,17,18,18-d6 acid | Cayman Chemical | 390030 | [2H6]-20-HETE Internal Standard |
9S-hydroxy-10E,12Z-octadecadienoic-9,10,12,13-d4 acid | Cayman Chemical | 338410 | [2H4]-9(S)-HODE Internal Standard |
13S-hydroxy-9Z,11E-octadecadienoic-9,10,12,13-d4 acid | Cayman Chemical | 338610 | [2H4]-13(S)-HODE Internal Standard |
9α,11α,15S-trihydroxy-prosta-5Z,13E-dien-1-oic-17,17,18,18,19,19,20,20,20-d4 acid | Cayman Chemical | 316010 | [2H4]-PGF2α Internal Standard |
9α,11α,15S-trihydroxy-(8β)-prosta-5Z,13E-dien-1-oic-3,3,4,4-d4 acid | Cayman Chemical | 316350 | [2H4]-8-iso-PGF2a Internal Standard |
9α,11β.,15S-trihydroxy-prosta-5Z,13E-dien-1-oic-3,3,4,4-d4 acid | Cayman Chemical | 10008989 | [2H4]-11β-PGF2 Internal Standard |
9α,15S-dihydroxy-11-oxo-prosta-5Z,13E-dien-1-oic-17,17,18,18,19,19,20,20,20-d4 acid | Cayman Chemical | 312010 | [2H4]-PGD2 Internal Standard |
9-oxo-11α,15S-dihydroxy-prosta-5Z,13E-dien-1-oic-17,17,18,18,19,19,20,20,20-d4 acid | Cayman Chemical | 314010 | [2H4]-PGE2 Internal Standard |
5S,12R-dihydroxy-6Z,8E,10E,14Z-eicosatetraenoic-6,7,14,15-d4 acid | Cayman Chemical | 320110 | [2H4]-LTB4 Internal Standard |
9α,11,15S-trihydroxy-thromba-5Z,13E-dien-1-oic-3,3,4,4-d4 acid | Cayman Chemical | 319030 | [2H4]-TxB2 Internal Standard |
5-oxo-6E,8Z,11Z,14Z-eicosatetraenoic acid | Cayman Chemical | 34250 | 5-ox–TE Standard |
12-oxo-5Z,8Z,10E,14Z-eicosatetraenoic acid | Cayman Chemical | 34580 | 12-ox–TE Standard |
15-oxo-5Z,8Z,11Z,13E-eicosatetraenoic acid | Cayman Chemical | 34730 | 15-ox–TE Standard |
5R-hydroxy-6E,8Z,11Z,14Z-eicosatetraenoic acid | Cayman Chemical | 34225 | 5(R)-HETE Standard |
5S-hydroxy-6E,8Z,11Z,14Z-eicosatetraenoic acid | Cayman Chemical | 34230 | 5(S)-HETE Standard |
8R-hydroxy-5Z,9E,11Z,14Z-eicosatetraenoic acid | Cayman Chemical | 34350 | 8(R)-HETE Standard |
8S-hydroxy-5Z,9E,11Z,14Z-eicosatetraenoic acid | Cayman Chemical | 34360 | 8(S)-HETE Standard |
11R-hydroxy-5Z,8Z,12E,14Z-eicosatetraenoic acid | Cayman Chemical | 34505 | 11(R)-HETE Standard |
11S-hydroxy-5Z,8Z,12E,14Z-eicosatetraenoic acid | Cayman Chemical | 34510 | 11(S)-HETE Standard |
12R-hydroxy-5Z,8Z,10E,14Z-eicosatetraenoic acid | Cayman Chemical | 34560 | 12(R)-HETE Standard |
12S-hydroxy-5Z,8Z,10E,14Z-eicosatetraenoic acid | Cayman Chemical | 34570 | 12(S)-HETE Standard |
15R-hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic acid | Cayman Chemical | 34710 | 15(R)-HETE Standard |
15S-hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic acid | Cayman Chemical | 34720 | 15(S)-HETE Standard |
20-hydroxy-5Z,8Z,11Z,14Z-eicosatetraenoic acid | Cayman Chemical | 90030 | 20-HETE Standard |
9R-hydroxy-10E,12Z-octadecadienoic acid | Cayman Chemical | 38405 | 9(R)-HODE Standard |
9S-hydroxy-10E,12Z-octadecadienoic acid | Cayman Chemical | 38410 | 9(S)-HODE Standard |
13R-hydroxy-9Z,11E-octadecadienoic acid | Cayman Chemical | 38605 | 13(R)-HODE Standard |
13S-hydroxy-9Z,11E-octadecadienoic acid | Cayman Chemical | 38610 | 13(S)-HODE Standard |
9α,11α,15S-trihydroxy-prosta-5Z,13E-dien-1-oic acid | Cayman Chemical | 16010 | PGF2α Standard |
9α,11α,15S-trihydroxy-(8β)-prosta-5Z,13E-dien-1-oic acid | Cayman Chemical | 16350 | 8-iso-PGF2α Standard |
9α,11β,15S-trihydroxy-prosta-5Z,13E-dien-1-oic acid | Cayman Chemical | 16520 | 11β-PGF2 Standard |
9α,15S-dihydroxy-11-oxo-prosta-5Z,13E-dien-1-oic acid | Cayman Chemical | 12010 | PGD2 Standard |
9-oxo-11α,15S-dihydroxy-(8β)-prosta-5Z,13E-dien-1-oic acid | Cayman Chemical | 14350 | 8-iso-PGE2 Standard |
9-oxo-11α,15S-dihydroxy-prosta-5Z,13E-dien-1-oic acid | Cayman Chemical | 14010 | PGE2 Standard |
5S,12R-dihydroxy-6Z,8E,10E,14Z-eicosatetraenoic acid | Cayman Chemical | 20110 | LTB4 Standard |
9α,11,15S-trihydroxythromba-5Z,13E-dien-1-oic acid | Cayman Chemical | 19030 | TxB2 Standard |
Phosphate Buffered Saline | GIBCO, by Life Technologies | 14190 | |
Diethyl Ether | Sigma-Aldrich | 346136 | |
Dichloromethane | Acros Organics | 61030-1000 | anhydrous |
N,N-diisopropylethyl amine | Sigma-Aldrich | 387649 | |
Pentafluorylbenzyl bromide | Sigma-Aldrich | 101052 | |
Hydrochloric Acid | Sigma-Aldrich | 320331 | |
Potassium Hydroxide | Fluka | 00650 | |
Acetonitrile | Fisher Scientific | A996-4 | |
Methanol | Fisher Scientific | A454-4 | |
Chloroform | Fisher Scientific | 366927 | |
Hexane | Fisher Scientific | H303-4 | |
Isopropanol | Fisher Scientific | A464-4 | |
Ethanol | Decon Laboratories | 2716 | |
Water | Fisher Scientific | W7-4 | |
Pasteur Pipets | Fisher Scientific | 13-678-200 | |
10 mL Glass Centrifuge Tubes | Kimble Chase | 73785-10 | Screw cap |
Phenolic Screw Caps | Kimble Chase | 73802-13415 | |
Chiralcel ADH Column | Chiral Technologies | 19325 | |
HPLC vials | Waters | 60000751CV | |
HPLC inserts | Waters | WAT094171 |
Demande d’autorisation pour utiliser le texte ou les figures de cet article JoVE
Demande d’autorisationThis article has been published
Video Coming Soon